Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation induction

2010 ◽  
Vol 94 (2) ◽  
pp. 678-683 ◽  
Author(s):  
Christopher P. Montville ◽  
Maram Khabbaz ◽  
Mira Aubuchon ◽  
Daniel B. Williams ◽  
Michael A. Thomas
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Pregnancy Rates ◽  
Clinical Pregnancy ◽  
Ovary Syndrome ◽  
Luteal Support ◽  
Clinical Pregnancy Rates

scholarly journals Impact of Luteal phase clomiphene citrate on endometrial thickness and clinical pregnancy rates in women with polycystic ovary syndrome

2020 ◽  
Vol 11 (3) ◽  
pp. 158-161
Author(s):  
Elsayed Elshamy ◽  
Ayman Soliman
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Luteal Phase ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
Clinical Pregnancy ◽  
Ovary Syndrome ◽  
Clinical Pregnancy Rates ◽  
Group 2 ◽  
Group 1

Objective: To compare between luteal phase clomiphene citrate and second cycle day clomiphene citrate on the thickness of the endometrium and clinical pregnancy rates in women with polycystic ovary syndrome. Methods: a prospective observational study conducted on 196 women with Polycystic ovary syndrome divided into two groups: Group 1 (98 patients) received 100mg of clomiphene citrate daily for 5 days starting on second cycle day and Group 2 (98 patients) received 100mg of clomiphene citrate daily starting in the luteal phase before onset of withdrawal bleeding for 5 days. Treatment and follow up applied for three cycles. Outcome measures were collected and analyzed and women who got pregnant were followed until 12 weeks of pregnancy. Results: no significant differences between the two groups regarding pre-ovulatory endometrial thickness (8.3mm in group 1vs 8.8mm in group 2), number of mature follicles (1.62 in group 1vs 1.57 in group 2) and mid-luteal serum progesterone levels(14.63ng/ml in group 1vs 14.9ng/ml in group 2). 34 women (35%) got pregnant in group 1 and 37 women (38%) in-group 2 and three patients had miscarriage in each group without any statistical significance. Conclusion: the present study does not support luteal clomiphene citrate over second cycle day clomiphene citrate to induce ovulation in infertile women with polycystic ovary syndrome.

scholarly journals METFORMIN USAGE TO INDUCE OVULATION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: META-ANALYSIS

2016 ◽  
Vol 8 (11) ◽  
pp. 86
Author(s):  
Laiza Maria Steimbach ◽  
Aline Dos Santos LouÇÃo ◽  
Claudia Batista Carraro ◽  
Fernanda Stumpf Tonin ◽  
Roberto Pontarolo ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Polycystic Ovary Syndrome ◽  
Odds Ratio ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Pregnancy Rates ◽  
Randomised Clinical Trials ◽  
Inclusion Criteria ◽  
Ovary Syndrome

Objective: To evaluate the use of MET in ovulation induction and pregnancy rates in a woman with polycystic ovary syndrome (PCOS).Methods: A meta-analysis of randomised clinical trials (RCT) that presented ovulation and gestation rates in women with PCOS, after administering CC or M et al. one or combined was performed. The studies were selected according to the inclusion criteria in PCOS patients, resistant to CC or not.Results: The meta-analysis demonstrated that MET and CC did not significantly increase the ovulation (Odds Ratio 1.72 [0.71, 4.12]) and gestation (OR 1.33 [0.88, 2.02]) rates when compared to the usage of CC itself in women not resistant to CC. However, in women with CC-resistant PCOS, the group treated with CC and MET presented higher rates of ovulation (Odds Ratio = 14.57 [4.96, 42.81]) and gestation (Odds Ratio = 11.86 [2.45, 57.36]) than patients treated only with CC.Conclusion: The combination of MET and CC did not show advantages over the administration of CC alone in women not resistant to CC. However, MET may show satisfactory results in women resistant to CC.

scholarly journals The Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome

2020 ◽  
Vol 36 (7) ◽  
Author(s):  
Mehmet Nafi Sakar ◽  
Süleyman Cemil Oğlak
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Live Birth ◽  
Ovulation Induction ◽  
Birth Rate ◽  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Live Birth Rate ◽  
Clinical Pregnancy ◽  
Ovary Syndrome ◽  
Live Birth Rates

Objective: This study was aimed to compare the clinical outcomes of ovulation induction (OI) by timed intercourse with letrozole (LTZ) and clomiphene citrate (CC). Methods: Three hundred and twenty-three patients with polycystic ovary syndrome (PCOS) who underwent OI with LTZ or CC between February 2017 and November 2018 were included in this retrospective study. The patients were divided into two groups as the CC group (n=148) and the LTZ group (n=175). Endometrial thickness, follicular development, ovulation, clinical pregnancy, abortion, and live birth rates of the groups were analyzed. Results: The mean endometrium thickness of the CC group was 7.1±1.7 mm, and the LTZ group was 8.6±1.8 mm (p<0.001). The ovulation rate per cycle was higher in the LTZ group (93.1%) in comparison with the CC group (83.8%) (p=0.013). Clinical pregnancy rates were 52% in the LTZ group, and 41.2% in the CC group (p=0.047). LTZ with 44% of live birth rate was superior to CC with a 33% live birth rate (p=0.029). Conclusions: LTZ is an effective OI agent in PCOS patients. LTZ is superior to CC in terms of pregnancy rates and live birth rates. As a result, we recommend that LTZ should be the first-line treatment agent in patients with PCOS. doi: https://doi.org/10.12669/pjms.36.7.3345 How to cite this:Sakar MN, Oglak SC. Letrozole is superior to clomiphene citrate in ovulation induction in patients with polycystic ovary syndrome. Pak J Med Sci. 2020;36(7):1460-1465. doi: https://doi.org/10.12669/pjms.36.7.3345 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Thyroxine Supplementation May Improve Ovulation and Pregnancy Rates in Infertile Patients with Polycystic Ovary Syndrome and Subclinical Hypothyroidism

2019 ◽  
Vol 3 (2) ◽  
pp. 01-05
Author(s):  
Hesham Ammar
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Subclinical Hypothyroidism ◽  
Ovulation Induction ◽  
Prospective Observational Study ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
Pregnancy Rates ◽  
Ovary Syndrome ◽  
Infertile Patients

This prospective observational study was conducted on 220 patients with polycystic ovary syndrome (PCOS) and subclinical hypothyroidism (SCH) who were allocated into two groups; group one (n=112) received clomiphene citrate (CC) plus thyroxine while group two received only CC for ovulation induction. Patients receiving CC and thyroxine exhibited higher ovulation rate (p<0.001), higher endometrial thickness (p<0.05), higher number of dominant follicles (p<0.001) and higher pregnancy rate (p<0.001) compared to their counterparts receiving only CC. Thyroxine supplementation improves ovulation and pregnancy rates in infertile patients with PCOS and SCH receiving CC for ovulation induction who are therapy naïve.

Sign in / Sign up

Export Citation Format

Share Document